MX2021015540A - Metodo para la generacion de una celula que expresa un anticuerpo trivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida. - Google Patents

Metodo para la generacion de una celula que expresa un anticuerpo trivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida.

Info

Publication number
MX2021015540A
MX2021015540A MX2021015540A MX2021015540A MX2021015540A MX 2021015540 A MX2021015540 A MX 2021015540A MX 2021015540 A MX2021015540 A MX 2021015540A MX 2021015540 A MX2021015540 A MX 2021015540A MX 2021015540 A MX2021015540 A MX 2021015540A
Authority
MX
Mexico
Prior art keywords
domain
light chain
heavy chain
chain variable
variable domain
Prior art date
Application number
MX2021015540A
Other languages
English (en)
Inventor
Ulrich Goepfert
Johannes Auer
Monika Popp
Christina-Lisa Hoeck
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2021015540A publication Critical patent/MX2021015540A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Abstract

La presente invención se refiere a un método para producir un anticuerpo trivalente que comprende las etapas de cultivar una célula de mamífero que comprende un ácido desoxirribonucleico que codifica el anticuerpo trivalente, y recuperar el anticuerpo trivalente de la célula o del medio de cultivo, en donde el ácido desoxirribonucleico que codifica el anticuerpo trivalente está integrado de forma estable en el genoma de la célula de mamífero y comprende en dirección 5' a 3' un primer casete de expresión que codifica la primera cadena pesada, un segundo casete de expresión que codifica la primera cadena ligera, un tercer casete de expresión que codifica la primera cadena ligera, un cuarto casete de expresión que codifica la segunda cadena pesada, un quinto casete de expresión que codifica la segunda cadena ligera, y un sexto casete de expresión que codifica la segunda cadena ligera, en donde la primera cadena pesada comprende desde el extremo N hasta el C un primer dominio variable de la cadena pesada, un dominio CH1, un primer dominio variable de la cadena ligera, un dominio CH1, una región bisagra, un dominio CH2 y un dominio CH3, la segunda cadena pesada comprende desde el extremo N hasta el C el primer dominio variable de la cadena pesada, un dominio CH1, una región bisagra, un dominio CH2 y un dominio CH3, la primera cadena ligera comprende desde el extremo N hasta el C un segundo dominio variable de la cadena pesada y un dominio CL, y la segunda cadena ligera comprende desde el extremo N hasta el C un segundo dominio variable de la cadena ligera y un dominio CL, en donde el primer dominio variable de la cadena pesada y el segundo dominio variable de la cadena ligera forman un primer sitio de unión y el segundo dominio variable de la cadena pesada y el primer dominio variable de la cadena ligera forman un segundo sitio de unión.
MX2021015540A 2019-06-19 2020-06-17 Metodo para la generacion de una celula que expresa un anticuerpo trivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida. MX2021015540A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19181095 2019-06-19
PCT/EP2020/066678 WO2020254352A1 (en) 2019-06-19 2020-06-17 Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization

Publications (1)

Publication Number Publication Date
MX2021015540A true MX2021015540A (es) 2022-02-10

Family

ID=67060256

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015540A MX2021015540A (es) 2019-06-19 2020-06-17 Metodo para la generacion de una celula que expresa un anticuerpo trivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida.

Country Status (11)

Country Link
US (1) US20220169729A1 (es)
EP (1) EP3986925A1 (es)
JP (2) JP7446342B2 (es)
KR (1) KR20220024637A (es)
CN (1) CN114008212A (es)
AU (1) AU2020296247A1 (es)
BR (1) BR112021025401A2 (es)
CA (1) CA3140287A1 (es)
IL (1) IL288968A (es)
MX (1) MX2021015540A (es)
WO (1) WO2020254352A1 (es)

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
WO1992008796A1 (en) 1990-11-13 1992-05-29 Immunex Corporation Bifunctional selectable fusion genes
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2163427A1 (en) 1993-05-21 1994-12-08 Stephen D. Lupton Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
LT2857516T (lt) 2000-04-11 2017-09-11 Genentech, Inc. Multivalentiniai antikūnai ir jų panaudojimas
MX2007000644A (es) 2004-07-20 2007-03-28 Symphogen As Anticuerpo policlonal recombinante anti-rhesus d y metodos de fabricacion.
BRPI0615397B1 (pt) * 2005-08-26 2023-10-03 Roche Glycart Ag Anticorpo anti-cd20, composição farmacêutica que o contém e uso do mesmo
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
ES2774337T3 (es) 2008-01-07 2020-07-20 Amgen Inc Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
AU2010230563A1 (en) 2009-04-02 2011-09-22 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain Fab fragments
US20100256340A1 (en) 2009-04-07 2010-10-07 Ulrich Brinkmann Trivalent, bispecific antibodies
MX2011011925A (es) 2009-05-27 2011-12-06 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos.
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
RS64179B1 (sr) 2011-05-27 2023-05-31 Hoffmann La Roche Dvostruko ciljanje
WO2013006142A1 (en) 2011-07-05 2013-01-10 Nanyang Technological University A novel process and reagent for rapid genetic alterations in eukaryotic cells
LT2748202T (lt) 2011-08-23 2018-09-25 Roche Glycart Ag Bispecifinės antigeną surišančios molekulės
EP3315514A1 (en) 2012-08-29 2018-05-02 F. Hoffmann-La Roche AG Blood brain barrier shuttle
EP2961771B1 (en) * 2013-02-26 2020-01-01 Roche Glycart AG Bispecific t cell activating antigen binding molecules specific to cd3 and cea
CN104342453A (zh) 2013-08-06 2015-02-11 深圳先进技术研究院 含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
NZ766556A (en) * 2014-08-04 2024-02-23 Hoffmann La Roche Bispecific t cell activating antigen binding molecules
CA2963696A1 (en) 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
CN107074955B (zh) 2014-11-20 2021-06-22 豪夫迈·罗氏有限公司 针对FolR1和CD3的T细胞活化性双特异性抗原结合分子
JP6930929B2 (ja) 2015-07-03 2021-09-01 エシロール アンテルナショナルＥｓｓｉｌｏｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ 拡張現実のための方法とシステム
CR20180162A (es) * 2015-10-02 2018-05-25 Hoffmann La Roche Moléculas biespecíficas de unión a antígeno activadoras de células t
CN110572195B (zh) 2016-03-25 2020-11-24 华为技术有限公司 一种天线端口的指示方法和装置
BR112018071285A2 (pt) 2016-04-20 2019-02-12 Regeneron Pharma célula, conjunto de vetores, vetor, sistema, e, método
KR102630357B1 (ko) 2017-02-17 2024-01-30 론자 리미티드 단백질 발현이 어려운 다중-부위 ssi 세포
PE20191360A1 (es) 2017-03-10 2019-10-01 Hoffmann La Roche Metodo para producir anticuerpos multiespecificos
JP7208380B2 (ja) 2018-10-26 2023-01-18 エフ．ホフマン－ラ ロシュ アーゲー リコンビナーゼ媒介性カセット交換を使用した多重特異性抗体スクリーニング法

Also Published As

Publication number Publication date
BR112021025401A2 (pt) 2022-02-01
JP2022537334A (ja) 2022-08-25
US20220169729A1 (en) 2022-06-02
JP7446342B2 (ja) 2024-03-08
WO2020254352A1 (en) 2020-12-24
EP3986925A1 (en) 2022-04-27
IL288968A (en) 2022-02-01
CA3140287A1 (en) 2020-12-24
KR20220024637A (ko) 2022-03-03
CN114008212A (zh) 2022-02-01
JP2024026208A (ja) 2024-02-28
AU2020296247A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
EA200900286A1 (ru) Модификация бактерий для получения этанола
NZ592308A (en) Non-human mammals for the production of chimeric antibodies
BRPI0613543B8 (pt) Método para produção de 1,3-propanodiol usando glicerol bruto, um subproduto da produção de biodiesel
SG171577A1 (en) Methods for producing yeast-based vaccines
UA92157C2 (ru) Способ продуцирования гормона роста
DE60029440D1 (de) Methoden und materialien zur synthese von organischen produkten
ATE444308T1 (de) Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
DE60323340D1 (de) Verfahren zur herstellung interferierender rna-moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
GB2424480A (en) Prostate stem cell
HUP9903774A2 (hu) Több herbicidtolerancia-gént tartalmazó kiméragének, több herbiciddel szemben toleráns növényi sejtek és növények
MX2021015537A (es) Metodo para la generacion de una celula que expresa anticuerpo biespecifico multivalente mediante la integracion diana de casetes de expresion multiples en una organizacion definida.
WO2004058822A3 (en) Generation of immunoglobulin molecules with predetermined specificity
MX2021015540A (es) Metodo para la generacion de una celula que expresa un anticuerpo trivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida.
MX2021015538A (es) Metodo para la generacion de una celula que expresa un anticuerpo biespecifico bivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida.
MX2021015648A (es) Metodo para la generacion de una celula que expresa un anticuerpo multiespecifico multivalente mediante integracion dirigida de multiples casetes de expresion en una organizacion definida.
MX2010004007A (es) Metodo para la produccion de un anticuerpo.
TW200506059A (en) Method for obtaining mastocyte lines from pig tissues and for producing heparin-type molecules
MX2009007790A (es) Mejora del crecimiento celular.
ES2168971B1 (es) Procedimiento de produccion de beta-caroteno.
DE60234787D1 (de) Blakeslea trispora zur herstellung von lycopin in hoher ausbeute, in einem geeigneten medium in abwesenheit eines exogenen corotenogenese-hemmstoffes
RU2017127208A (ru) Строение экспрессионного вектора, новые способы получения клеток-продуцентов и их применение для рекомбинантного получения полипептидов
ATE416156T1 (de) Verfahren zur herstellung von acetessigsäurearylamiden
Steuer Fast‐growing phototrophic microorganisms and the productivity of phototrophic cultures
WO2007095336A3 (en) Production of hiv
EP1517987A4 (en) LUNG CELLS OF COTTON RATES TO VIRUS CULTURE